EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSAPEG00000015076
Gene Symbol: GART
1 Cross references
212 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSAPEG00000017076
Gene Symbol: PLAT
1 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSAPEG00000017518
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSAPEG00000016406
Gene Symbol: PDGFRB
1 Cross references
199 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSAPEG00000011207
Gene Symbol: PLK1
2 Cross references
187 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSAPEG00000020186
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSAPEG00000016950
Gene Symbol: PARP3
1 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSAPEG00000021068
Gene Symbol: PORCN
1 Cross references
195 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSAPEG00000014751
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSAPEG00000013012
Gene Symbol: KCNMA1
1 Cross references
226 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSAPEG00000010838
Gene Symbol: KCNMA1
1 Cross references
225 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSAPEG00000013824
Gene Symbol: KCNMA1
1 Cross references
242 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).